Awardee OrganizationUNIVERSITY OF TEXAS HLTH SCIENCE CENTER
Description
Abstract Text
The determination and terminal differentiation of adipose cells results
in the initiation of the expression of a large number of adipocyte-
specific genes, a coordinate rise in their mRNA levels and an increased
responsiveness to insulin. The overall objective of this proposed work
are: 1) to define the molecular mechanism by which a lipogenic hormone,
insulin, controls adipocyte gene activity, and 2) to understand the
biochemical changes that occur during the process of preadipocyte cell
commitment to the terminally differentiated adipocyte phenotype. This
complex series of events involved in adipocyte differentiation will be
analyzed using the murine 3T3-L1 cell line and the gene encoding the
CCAAT/Enhancer Binding Protein (C/EBP). 3T3-L1 cells differentiate with
proper hormonal stimuli from fibroblast-like preadipocyte cells to mature
adipocytes. the 3T3-L1 system has a well characterized adipose
differentiation program and are highly responsive to insulin, making it
an excellent model for analysis of insulin action and preadipose cell
commitment. C-EBP has been shown to be involved in the development of
the terminally differentiated adipocyte and the regulation of adipocyte-
specific gene expression. Previous studies have shown that there are
several cis-elements in the 5' flanking sequence of the C-EBP gene that
interact with 3T3-L1 nuclear proteins, and have an altered DNaseI
sensitivity pattern upon adipocyte differentiation, which may be
important in C-EBP gene regulation. Recent data from our laboratory has
shown that C/EBP mRNA levels are altered by insulin in 3T3-L1 adipocyte
cells. Analysis of earlier events in the regulatory pathways involved
in the cascade of preadipocyte to adipocyte cell commitment and the
effects of insulin on the lipogenic regulatory factor, C/EBP, will be
tested by the following specific aims. First, we will determine hormonal
effects on C/EBP mRNA levels in vivo. Nuclear run-on transcription assay
will be used to assay alterations in rates of transcription of the C/EBP
gene in adipocytes by insulin, diet and other hormones. Second, we will
analyze the mechanisms that control C/EBP gene activity using CAT
reporter constructs containing the C/EBP promoter in transfection
expression assays in 3T3-L1 cells. Third, since C/EBP is expressed only
in the differentiated 3T3-L1 adipocytes we will identify the preadipocyte
specific DNA-binding protein(s), a putative repressor of gene activity,
that interacts with the 5' flanking sequence of the C/EBP gene, using a
preadipocyte expression library. The fourth aim of this project is to
analyze the elements in the 5' flanking region of the C/EBP gene that
interact with the immediate early gene product Zif268, C/EBP gene
product, and HLH proteins.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
DUNS Number
800772162
UEI
C3KXNLTAAY98
Project Start Date
01-May-1993
Project End Date
30-April-1998
Budget Start Date
01-May-1995
Budget End Date
30-April-1996
Project Funding Information for 1995
Total Funding
$101,500
Direct Costs
$70,000
Indirect Costs
$31,500
Year
Funding IC
FY Total Cost by IC
1995
National Institute of Diabetes and Digestive and Kidney Diseases
$101,500
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R29DK046360-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R29DK046360-03
Patents
No Patents information available for 5R29DK046360-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R29DK046360-03
Clinical Studies
No Clinical Studies information available for 5R29DK046360-03
News and More
Related News Releases
No news release information available for 5R29DK046360-03
History
No Historical information available for 5R29DK046360-03
Similar Projects
No Similar Projects information available for 5R29DK046360-03